Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Nuclear Medicine Physician in Pittsburgh, PA
NPI: 1245437250HQ Phone
Get M.D. David's Phone Numberphone_androidMobile
Get M.D. David's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2011 - 2027
NY State Medical License
2010 - 2012
PA State Medical License
2010 - 2012
American Board of Nuclear Medicine
Nuclear Medicine
Certification Board of Nuclear Cardiology
Nuclear Cardiology
The Johns Hopkins University School of Medicine
hopkinsmedicine.org
Fellowship • PET/CT
2010 - 2011
Johns Hopkins University
Residency • Nuclear Medicine
2007 - 2010
UC Davis School of Medicine
health.ucdavis.edu
Medical School
Until 2006
New York-Presbyterian/Queens
Internship • Internal Medicine
2006 - 2007
A randomized, double‐blind, single‐dose, three‐arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (Soliris®) in healthy male subjects
Authors: Vincent Chow, Jean Pan, David Chien, Daniel T. Mytych, Vladimir Hanes
Publication Date: 2020-03
Authors: Mehmet Bilen, Arjun Balar, Maged Khalil, Mary Tagliaferri, Vadim Koshkin, Arlene Siefker-Radtke
Journal: Future Oncol
Publication Date: 2020-09-17
Lead Sponsor: Nektar Therapeutics
Collaborators: Merck Sharp & Dohme LLC, SFJ Pharmaceuticals, Inc.
Intervention / Treatment: DRUG: Pembrolizumab, DRUG: Bempegaldesleukin
Lead Sponsor: University of Wisconsin, Madison
Collaborators: Nektar Therapeutics
Intervention / Treatment: DRUG: NKTR-214, DRUG: anti-PD-1 therapy, RADIATION: Palliative Radiation
Lead Sponsor: Bristol-Myers Squibb
Collaborators: Nektar Therapeutics
Intervention / Treatment: BIOLOGICAL: Nivolumab, BIOLOGICAL: NKTR-214